Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)


Engel Law PLLC is investigating whether fair value to Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shareholders will result from the proposed acquisition of Zynerba by Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY) for (i) $1.1059 in cash, plus (ii) one non-tradable contingent value right per share (representing the right to receive potential additional payments of up to $140 million subject to the achievement of certain clinical, regulatory and sales milestones for Zygel — Zynerba’s lead new drug candidate) for each Zynerba share.

The Firm’s investigation concerns:

(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Join this Action

Zynerba Pharmaceuticals, Inc.

MM slash DD slash YYYY